ATE544847T1 - Verwendung von dendritischen zellen, die interleukin 12 (il-12) exprimieren - Google Patents

Verwendung von dendritischen zellen, die interleukin 12 (il-12) exprimieren

Info

Publication number: ATE544847T1
Authority: AT; Austria
Prior art keywords: cells expressing; dendritic cells; expressing interleukin; interleukin; dendritic
Prior art date: 2002-09-13

Application number

AT03794972T

Other languages

English (en)

Inventor

Thomas Felzmann

Original Assignee

Forsch Krebskranke Kinder

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-13

Filing date

2003-08-29

Publication date

2012-02-15

2003-08-29 Application filed by Forsch Krebskranke Kinder filed Critical Forsch Krebskranke Kinder

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE544847T1 publication Critical patent/ATE544847T1/de

Links

102000013462 Interleukin-12 Human genes 0.000 title 2
108010065805 Interleukin-12 Proteins 0.000 title 2
229940117681 interleukin-12 Drugs 0.000 title 2

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/53—Liver
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/56—Kidney
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/052—Lipopolysaccharides [LPS]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT03794972T 2002-09-13 2003-08-29 Verwendung von dendritischen zellen, die interleukin 12 (il-12) exprimieren ATE544847T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AT0137502A AT412145B (de)	2002-09-13	2002-09-13	Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
PCT/EP2003/009591 WO2004024900A1 (en)	2002-09-13	2003-08-29	USE OF DENDRITIC CELLS (DCs) EXPRESSING INTERLEUKIN 12 (IL-12)

Publications (1)

Publication Number	Publication Date
ATE544847T1 true ATE544847T1 (de)	2012-02-15

Family

ID=31892564

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT0137502A AT412145B (de)	2002-09-13	2002-09-13	Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
AT03794972T ATE544847T1 (de)	2002-09-13	2003-08-29	Verwendung von dendritischen zellen, die interleukin 12 (il-12) exprimieren

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT0137502A AT412145B (de)	2002-09-13	2002-09-13	Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen

Country Status (12)

Country	Link
US (1)	US7867488B2 (de)
EP (1)	EP1537203B1 (de)
JP (1)	JP2005538167A (de)
AT (2)	AT412145B (de)
AU (1)	AU2003260473B2 (de)
CA (1)	CA2494216C (de)
CY (1)	CY1112740T1 (de)
DK (1)	DK1537203T3 (de)
ES (1)	ES2381870T3 (de)
PT (1)	PT1537203E (de)
SI (1)	SI1537203T1 (de)
WO (1)	WO2004024900A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE602004023238D1 (de) *	2004-05-11	2009-10-29	Shukokai Inc	Methoden zur Kultivierung von Antigen presentierenden Immunzellen
CA2632263C (en) *	2005-12-08	2022-01-11	Northwest Biotherapeutics, Inc.	Compositions and methods for inducing the activation of immature monocytic dendritic cells
AU2013206016B2 (en) *	2005-12-08	2016-08-11	Northwest Biotherapeutics, Inc.	Compositions and methods for inducing the activation of immature monocytic dendritic cells
EP2072617A1 (de) *	2007-12-12	2009-06-24	Trimed Biotech GmbH	Verfahren zur Herstellung dendritischer Zellen
RU2575978C2 (ru) *	2010-03-15	2016-02-27	Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания	Система и способ получения и хранения активированных зрелых дендритных клеток
GB2534478A (en) *	2012-06-27	2016-07-27	Hasumi Int Res Found	Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
WO2014149871A1 (en) *	2013-03-14	2014-09-25	Icahn School Of Medicine At Mount Sinai	Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
EP2787005A1 (de)	2013-04-02	2014-10-08	Activartis Biotech GmbH	Gezielte Krebs-Immuntherapie
KR102091748B1 (ko) *	2018-05-04	2020-03-20	차의과학대학교 산학협력단	수지상세포의 이동능을 증가시키는 방법 및 이의 용도
US12605349B2 (en)	2024-09-05	2026-04-21	Orbus Therapeutics, Inc.	Methods of treating grade 3 astrocytoma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6479254B2 (en) *	1996-03-22	2002-11-12	Human Genome Sciences, Inc.	Apoptosis inducing molecule II
FR2796961B1 (fr) *	1999-07-29	2003-05-02	Chu Montpellier	Procede d'obtention de cellules dentritiques, les cellules dentritiques ainsi obtenues et leurs utilisations a des fins cliniques
US20010049357A1 (en) *	1999-12-03	2001-12-06	De Asit K.	Use of Hsp27 as an anti-inflammatory agent
WO2001051077A1 (en) *	2000-01-14	2001-07-19	The Government Of The United States Of Americarep Resented By The Secretary, Department Of Health And Human Services	Methods of regulating il-12 production by administering ccr5 agonists and antagonists
US20030003579A1 (en) *	2000-10-24	2003-01-02	Norimitsu Kadowaki	Dendritic cells; methods
EP2322603B1 (de) *	2001-09-06	2019-10-16	NorthWest Biotherapeutics, Inc.	Zusammensetzungen und Verfahren für die Aktivierung von monocytischen Dendritischen Zellen und T-Zellen auf Th1-Antwort

2002
- 2002-09-13 AT AT0137502A patent/AT412145B/de not_active IP Right Cessation
2003
- 2003-08-29 AT AT03794972T patent/ATE544847T1/de active
- 2003-08-29 AU AU2003260473A patent/AU2003260473B2/en not_active Ceased
- 2003-08-29 DK DK03794972.4T patent/DK1537203T3/da active
- 2003-08-29 PT PT03794972T patent/PT1537203E/pt unknown
- 2003-08-29 ES ES03794972T patent/ES2381870T3/es not_active Expired - Lifetime
- 2003-08-29 US US10/527,679 patent/US7867488B2/en not_active Expired - Lifetime
- 2003-08-29 SI SI200332142T patent/SI1537203T1/sl unknown
- 2003-08-29 CA CA2494216A patent/CA2494216C/en not_active Expired - Fee Related
- 2003-08-29 EP EP03794972A patent/EP1537203B1/de not_active Expired - Lifetime
- 2003-08-29 WO PCT/EP2003/009591 patent/WO2004024900A1/en not_active Ceased
- 2003-08-29 JP JP2004535211A patent/JP2005538167A/ja active Pending
2012
- 2012-05-08 CY CY20121100427T patent/CY1112740T1/el unknown

Also Published As

Publication number	Publication date
ES2381870T3 (es)	2012-06-01
US7867488B2 (en)	2011-01-11
SI1537203T1 (sl)	2012-06-29
PT1537203E (pt)	2012-05-21
EP1537203B1 (de)	2012-02-08
AT412145B (de)	2004-10-25
AU2003260473B2 (en)	2008-08-07
AU2003260473A1 (en)	2004-04-30
DK1537203T3 (da)	2012-05-14
JP2005538167A (ja)	2005-12-15
US20060177420A1 (en)	2006-08-10
ATA13752002A (de)	2004-03-15
CA2494216A1 (en)	2004-03-25
EP1537203A1 (de)	2005-06-08
CY1112740T1 (el)	2016-02-10
WO2004024900A1 (en)	2004-03-25
CA2494216C (en)	2013-07-09

Publication	Publication Date	Title
ITTO20040797A1 (it)	2005-02-12	Composizione per il rimpiazzo di carboidrati ed elettroliti.
NO20054078D0 (no)	2005-09-01	Humane antistoffer spesifikke for Interleukin 15 (IL15).
AU2003253897A1 (en)	2004-02-02	Dendritic cell pontentiation
DE60010921D1 (de)	2004-06-24	Künstliche chromosomen, die die genetische information für die bildung von rekombinantem rna-virus enthalten
DE60315019D1 (de)	2007-08-30	Entfernbarer hydraulikschlauchträger
DE50313510D1 (de)	2011-04-14	Zellkultureinsatz
EP1492180A4 (de)	2010-06-23	Positiv-elektrodenmaterial für eine lithium-sekundärzelle und sekundärzelle damit und verfahren zur herstellung eines positiv-elektrodenmaterials für eine lithium-sekundärzelle
AUPS076802A0 (en)	2002-03-21	Selective nucleic acid amplification
AU2003220249A1 (en)	2003-09-29	Improved nucleic acid amplification
AU2003287521A1 (en)	2004-06-03	Pluripotent cells from monocytes, and methods of making and using pluripotent cells
IS7609A (is)	2004-12-22	2,5-tvíútskipt 3-merkaptópentansýra
ITMI20022704A1 (it)	2004-06-21	Procedimento per la produzione di mesitilene e durene.
ITTV20030108A1 (it)	2005-01-30	Lastra sottile, stratificata e rinforzata e procedimento per la sua fabbricazione.
AU2003284127A8 (en)	2004-05-04	Nucleic acid supported protein complementation
SI1537203T1 (sl)	2012-06-29	Uporaba dendritičnih celic (DC), ki eksprimirajo interlevkin 12 (IL-12)
DK1573016T3 (da)	2014-07-28	Genreporterassay, -kit og -celler.
DE50303362D1 (de)	2006-06-22	Kraftaufnehmer
WO2004075315A3 (en)	2004-11-18	Battery containing fibrous material
DE60018253D1 (de)	2005-03-31	Die Verwendung von 5-Carboxanilido-2,4-bis-trifluoromethylthiazole gegen Reisbräune
NO20044120L (no)	2004-09-28	Elektrolytisk diafragmacelle
DE50302820D1 (de)	2006-05-18	Kraftaufnehmer
DE10390251D2 (de)	2004-12-23	Trojanische Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung
AU2003219570A1 (en)	2003-10-13	Novel dendritic cell-specific polynucleotides and microarray comprising the same
ITUD20020247A1 (it)	2004-05-27	Procedimento per controllare e condizionare il comportamento dell'acaro varroa destructor in un alveare, o in un altro ambiente in cui si riproducono le api.
ITBG20020034A1 (it)	2004-04-22	Struttura di pattino migliorata.